FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1504137925> ?p ?o ?g. }

• W1504137925 endingPage "92" @default.
• W1504137925 startingPage "87" @default.
• W1504137925 abstract "Objectives To investigate whether 7‐[2‐[4‐(2‐chlorophenyl) piperazinyl] ethyl]‐1,3‐di‐methylxanthine ( KMUP ‐1) inhibits the effects of testosterone on the development of benign prostatic hyperplasia and sensitizes prostate contraction. Methods A benign prostatic hyperplasia animal model was established by subcutaneous injections of testosterone (3 mg/kg/day, s.c.) for 4 weeks in adult male S prague– D awley rats. Animals were divided into six groups: control, testosterone, testosterone with KMUP ‐1 (2.5, 5 mg/kg/day), sildenafil (5 mg/kg/day) or doxazosin (5 mg/kg/day). After 4 weeks, the animals were killed, and prostate tissues were prepared for isometric tension measurement and western blotting analysis. KMUP‐1, Y 27632, zaprinast, doxazosin or tamsulosin were used at various concentrations to determine the contractility sensitized by phenylephrine (10 μmol/L). Results KMUP ‐1 inhibited testosterone‐induced phosphorylation of extracellular signal‐regulated phosphorylated protein kinase and mitogen‐activated protein kinase kinase and R ho kinase‐ II activation. Sildenafil and doxazosin significantly decreased benign prostatic hyperplasia‐induced mitogen‐activated protein kinase kinase and R ho kinase‐ II activation. The decreased expressions of soluble guanylate cyclase α 1 was reversed by KMUP ‐1, doxazosin and sildenafil. Soluble guanylate cyclase β 1 and protein kinase G were increased by KMUP ‐1, doxazosin, and sildenafil in the testosterone‐treated benign prostatic hyperplasia group. Phosphodiesterase‐5 A was increased by testosterone and inhibited by KMUP ‐1 (5 mg/kg/day) or sildenafil (5 mg/kg/day). KMUP ‐1 inhibited phenylephrine‐sensitized prostate contraction of rats treated with testosterone. Conclusions Mitogen‐activated protein kinase 1/extracellular regulated protein kinases kinase, soluble guanylate cyclase/cyclic guanosine monophosphate, protein kinase/protein kinase G and R ho kinase‐ II are related to prostate smooth muscle tone and proliferation induced by testosterone. KMUP ‐1 inhibits testosterone‐induced prostate hyper‐contractility and mitogen‐activated protein kinase 1/extracellular regulated protein kinases kinase‐phosphorylation, and it inactivates R ho kinase‐ II by cyclic guanosine monophosphate, protein kinase and α1 A ‐adenergic blockade. Thus, KMUP ‐1 might be a beneficial pharmacotherapy for benign prostatic hyperplasia." @default.
• W1504137925 created "2016-06-24" @default.
• W1504137925 creator A5005286005 @default.
• W1504137925 creator A5005754971 @default.
• W1504137925 creator A5007695335 @default.
• W1504137925 creator A5011615090 @default.
• W1504137925 creator A5024624236 @default.
• W1504137925 creator A5063629920 @default.
• W1504137925 date "2013-05-20" @default.
• W1504137925 modified "2023-10-17" @default.
• W1504137925 title "Cyclic guanosine monophosphate-enhancing reduces androgenic extracellular regulated protein kinases-phosphorylation/Rho kinase II-activation in benign prostate hyperplasia" @default.
• W1504137925 cites W1503549916 @default.
• W1504137925 cites W1625425402 @default.
• W1504137925 cites W1963584997 @default.
• W1504137925 cites W1966468989 @default.
• W1504137925 cites W1968868091 @default.
• W1504137925 cites W1981213058 @default.
• W1504137925 cites W1985689558 @default.
• W1504137925 cites W1990260193 @default.
• W1504137925 cites W2019727983 @default.
• W1504137925 cites W2025326001 @default.
• W1504137925 cites W2032286800 @default.
• W1504137925 cites W2039955270 @default.
• W1504137925 cites W2054403476 @default.
• W1504137925 cites W2054543612 @default.
• W1504137925 cites W2056149489 @default.
• W1504137925 cites W2059642159 @default.
• W1504137925 cites W2072252889 @default.
• W1504137925 cites W2081673273 @default.
• W1504137925 cites W2091083756 @default.
• W1504137925 cites W2092996139 @default.
• W1504137925 cites W2106293831 @default.
• W1504137925 cites W2109543271 @default.
• W1504137925 cites W2122467002 @default.
• W1504137925 cites W2136289786 @default.
• W1504137925 cites W2141798784 @default.
• W1504137925 cites W2149194464 @default.
• W1504137925 cites W2334465650 @default.
• W1504137925 doi "https://doi.org/10.1111/iju.12195" @default.
• W1504137925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23692571" @default.
• W1504137925 hasPublicationYear "2013" @default.
• W1504137925 type Work @default.
• W1504137925 sameAs 1504137925 @default.
• W1504137925 citedByCount "6" @default.
• W1504137925 countsByYear W15041379252013 @default.
• W1504137925 countsByYear W15041379252014 @default.
• W1504137925 countsByYear W15041379252015 @default.
• W1504137925 countsByYear W15041379252016 @default.
• W1504137925 crossrefType "journal-article" @default.
• W1504137925 hasAuthorship W1504137925A5005286005 @default.
• W1504137925 hasAuthorship W1504137925A5005754971 @default.
• W1504137925 hasAuthorship W1504137925A5007695335 @default.
• W1504137925 hasAuthorship W1504137925A5011615090 @default.
• W1504137925 hasAuthorship W1504137925A5024624236 @default.
• W1504137925 hasAuthorship W1504137925A5063629920 @default.
• W1504137925 hasConcept C126322002 @default.
• W1504137925 hasConcept C134018914 @default.
• W1504137925 hasConcept C184235292 @default.
• W1504137925 hasConcept C185592680 @default.
• W1504137925 hasConcept C2776768464 @default.
• W1504137925 hasConcept C2777590997 @default.
• W1504137925 hasConcept C2780994212 @default.
• W1504137925 hasConcept C519581460 @default.
• W1504137925 hasConcept C55493867 @default.
• W1504137925 hasConcept C57074206 @default.
• W1504137925 hasConcept C71924100 @default.
• W1504137925 hasConcept C84393581 @default.
• W1504137925 hasConcept C97029542 @default.
• W1504137925 hasConcept C98274493 @default.
• W1504137925 hasConceptScore W1504137925C126322002 @default.
• W1504137925 hasConceptScore W1504137925C134018914 @default.
• W1504137925 hasConceptScore W1504137925C184235292 @default.
• W1504137925 hasConceptScore W1504137925C185592680 @default.
• W1504137925 hasConceptScore W1504137925C2776768464 @default.
• W1504137925 hasConceptScore W1504137925C2777590997 @default.
• W1504137925 hasConceptScore W1504137925C2780994212 @default.
• W1504137925 hasConceptScore W1504137925C519581460 @default.
• W1504137925 hasConceptScore W1504137925C55493867 @default.
• W1504137925 hasConceptScore W1504137925C57074206 @default.
• W1504137925 hasConceptScore W1504137925C71924100 @default.
• W1504137925 hasConceptScore W1504137925C84393581 @default.
• W1504137925 hasConceptScore W1504137925C97029542 @default.
• W1504137925 hasConceptScore W1504137925C98274493 @default.
• W1504137925 hasIssue "1" @default.
• W1504137925 hasLocation W15041379251 @default.
• W1504137925 hasLocation W15041379252 @default.
• W1504137925 hasOpenAccess W1504137925 @default.
• W1504137925 hasPrimaryLocation W15041379251 @default.
• W1504137925 hasRelatedWork W1504137925 @default.
• W1504137925 hasRelatedWork W1991969187 @default.
• W1504137925 hasRelatedWork W2008087125 @default.
• W1504137925 hasRelatedWork W2067160292 @default.
• W1504137925 hasRelatedWork W2070643674 @default.
• W1504137925 hasRelatedWork W2116538667 @default.
• W1504137925 hasRelatedWork W2409608972 @default.
• W1504137925 hasRelatedWork W2419118008 @default.
• W1504137925 hasRelatedWork W2748952813 @default.
• W1504137925 hasRelatedWork W4254421120 @default.

• next